[JM216, an orally active platine derivative].
Lansiaux
A
A
Laboratoire de pharmacologie antitumorale du centre Oscar-Lambret, et Unité 524 Inserm, place de Verdun, 59045 Lille Cedex, France.
Bailly
C
C
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D002945:Cisplatin / Q000378:metabolism; D002986:Clinical Trials as Topic; D018736:DNA Adducts / Q000378:metabolism; D004273:DNA, Neoplasm / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D051379:Mice; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D018736:DNA Adducts; D004273:DNA, Neoplasm; D009944:Organoplatinum Compounds; C057270:cisplatin-DNA adduct; C081294:satraplatin; D002945:Cisplatin